Genprex Shares Rally on European Patent Approval

Biotechnology firm Genprex is demonstrating unexpected momentum following a period of challenging financial results and a significant reverse stock split. The recent surge appears directly linked to strengthened intellectual property rights for its flagship cancer therapy in Europe, raising questions about the potential for a durable recovery.

The primary catalyst for the recent positive price movement emerged on November 4th. The European Patent Office indicated it would grant a patent for Genprex's Reqorsa gene therapy, specifically for its use in combination with PD-1 antibodies for cancer treatment. This development substantially bolsters the company's IP protection in a crucial market, complementing patents already secured in the United States, Japan, and China. Market participants are now assessing whether this patent grant could signal the long-awaited inflection point for the clinical-stage company.

Quarterly Results Contrast with Market Reaction

Despite the optimistic patent news, the company's fundamental performance tells a different story. On Friday, Genprex released its financial report for the third quarter of 2025, revealing an adjusted loss per share of $5.00. Contrary to what such disappointing figures might suggest, the stock defied logic by climbing 7.00 percent to close at $4.43. Trading volume for the session remained subdued, however, with only 197,000 shares changing hands, a figure well below average activity levels.

Should investors sell immediately? Or is it worth buying Genprex?

Reverse Split Executed to Maintain Listing

Prior to these developments, on October 21st, the company undertook a 1-for-50 reverse stock split. This corporate action drastically reduced the number of outstanding shares to approximately one million. Such a maneuver is typically employed to regain compliance with minimum share price requirements for continued listing on the NASDAQ exchange. It is important for investors to note that a reverse split does not generate new capital for the company.

Technical and Analytical Outlook

From a technical perspective, the stock appears to be in oversold territory, with its 14-day Relative Strength Index (RSI) standing at 24. Despite this technical signal, several analyst platforms maintain a "Sell" rating on the equity. All attention is now focused on the upcoming clinical milestones for Reqorsa and the company's diabetes candidate, GPX-002. The next quarterly report, scheduled for May 2026, is highly anticipated as it will provide critical evidence to determine if the current wave of optimism is fundamentally justified.